On September 5, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, amended its bridge loan agreement with AutoMax Motors Ltd., providing an additional $1.85 million loan. This amendment brings the total loan amount to $4.25 million. The loan is secured by a first-ranking fixed charge on shares of AutoMax's subsidiary, AutoMax Leasing Ltd. The amendment is part of a broader agreement that includes a merger plan between SciSparc and AutoMax, initially dated April 10, 2024. Due to the loan, the previously agreed closing financing from SciSparc to AutoMax will no longer occur. AutoMax, through AutoMax Leasing, has also entered into a direct import agreement with JAC Motors, a major Chinese vehicle manufacturer. SciSparc focuses on developing treatments for central nervous system disorders and rare diseases and has several drug development programs underway. The company plans to file a registration statement and a proxy statement with the SEC in connection with the proposed transactions, and advises investors and shareholders to read these documents once available.

On September 5, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, amended its bridge loan agreement with AutoMax Motors Ltd., providing an additional $1.85 million loan. This amendment brings the total loan amount to $4.25 million. The loan is secured by a first-ranking fixed charge on shares of AutoMax's subsidiary, AutoMax Leasing Ltd. The amendment is part of a broader agreement that includes a merger plan between SciSparc and AutoMax, initially dated April 10, 2024. Due to the loan, the previously agreed closing financing from SciSparc to AutoMax will no longer occur. AutoMax, through AutoMax Leasing, has also entered into a direct import agreement with JAC Motors, a major Chinese vehicle manufacturer. SciSparc focuses on developing treatments for central nervous system disorders and rare diseases and has several drug development programs underway. The company plans to file a registration statement and a proxy statement with the SEC in connection with the proposed transactions, and advises investors and shareholders to read these documents once available.